End-to-End Immunopeptidomics Services: From Sample to Neoantigen Discovery
- Identification of targets for personalized cancer vaccines and T cell-based therapies
- Evaluation of tumor immunogenicity and antigen escape mechanisms
- Characterization of antigen presentation landscapes in viral infections and autoimmune diseases
- Support for mechanistic studies and toxicity assessment in drug development
Tumor immunotherapy has undergone rapid advancement in recent years. From immune checkpoint inhibitors to personalized vaccines and TCR-T cell therapies, strategies aimed at precisely activating T cell recognition of tumor cells are increasingly regarded as a central direction in next-generation cancer treatment. Neoantigens, defined as novel peptide sequences arising from tumor-specific genetic mutations, represent ideal targets for eliciting tumor-specific immune responses due to their strong non-self immunogenicity. However, neoantigen identification remains highly challenging. Although in silico prediction of MHC-binding peptides offers moderate throughput, it is limited by high false-positive rates and uncertain functional relevance. Particularly in the context of personalized therapy, prediction-based approaches alone are insufficient to accurately capture the actual presentation landscape of neoantigens in vivo.
In this context, immunopeptidomics, a mass spectrometry-based approach for directly profiling peptides presented by MHC complexes, has emerged as a critical strategy for neoantigen discovery. Unlike predictive methods, immunopeptidomics provides an empirical view of antigen presentation, enabling the direct identification of peptides naturally presented by MHC molecules under physiological conditions, thereby offering biologically relevant evidence for neoantigen validation and target development.
Technical Principles And Workflow Analysis Of Immunopeptidomics
The core principle of immunopeptidomics involves the enrichment of MHC complexes via immunoprecipitation, followed by the release of bound peptides and their identification using high-resolution mass spectrometry, thereby reconstructing the endogenous antigen presentation landscape. The workflow comprises the following key steps:
1. Sample Preparation
A wide range of sample types is supported, including tumor tissues, cell lines, and PBMCs. Sample preprocessing should prioritize the preservation of peptide integrity while minimizing degradation.
2. MHC Immunoprecipitation (IP)
Specific antibodies are employed to selectively enrich MHC class I or class II complexes, ensuring the specificity of peptide origin and representing a critical determinant of overall workflow performance.
3. Peptide Elution And Purification
Bound peptides are gently eluted from MHC molecules באמצעות mild acid treatment, followed by purification using solid-phase extraction to remove contaminants and non-specific components.
4. Mass Spectrometry Analysis (LC-MS/MS)
High-resolution mass spectrometry platforms (e.g., Orbitrap Exploris or timsTOF) are utilized for the accurate identification and quantification of short peptides, typically 8-15 amino acids in length.
5. Database Matching And Neoantigen Screening
Mass spectrometry data are matched against personalized peptide databases constructed from patient-specific mutation data (e.g., WES or RNA-seq), enabling the identification of mutation-derived peptides as candidate neoantigens.
Technical Challenges And Key Optimization Points
Despite its significant advantages, immunopeptidomics remains technically demanding and requires careful optimization in several key aspects:
1. Enrichment Of Low-Abundance Peptides
Neoantigens are typically present at low abundance, making the optimization of antibody selection and immunoprecipitation conditions essential.
2. Sensitivity And Identification Efficiency For Short Peptides
Compared with conventional proteomics workflows, immunopeptidomics places greater demands on instrument sensitivity and optimized mass spectrometry parameters.
3. High-Confidence Peptide Identification Algorithms
Robust data analysis requires the integration of multiple computational tools (e.g., NetMHCpan, MixMHCpred) in combination with stringent false discovery rate (FDR) control to ensure identification accuracy.
Application Value: Bridging Omics Data And Therapeutic Targets
Immunopeptidomics is increasingly recognized as a key bridge linking omics data to actionable therapeutic targets. Its applications include:
Within the framework of precision medicine, immunopeptidomics shifts antigen validation from a prediction-driven paradigm to an evidence-based approach grounded in directly presented peptides, thereby enhancing both translational efficiency and clinical success rates.
As personalized cancer immunotherapy continues to advance, the identification of truly presented neoantigens is emerging as a critical frontier in drug development and target discovery. Immunopeptidomics not only improves the reliability of neoantigen identification but also provides a biologically grounded framework for discovery. MtoZ Biolabs remains committed to leveraging advanced mass spectrometry technologies to support the full immunotherapy development pipeline, enabling researchers to capture authentic immune recognition signals and accelerate the clinical translation of precision medicine.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
